© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good afternoon. My name is Joey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Integer Holdings Q4 2017 Earnings Conference Call. [Operator Instructions] Thank you.
Amy Wakeham, you may begin your conference.
Great. Thanks Joey. Good afternoon, everyone. Thanks for joining us and welcome to Integer's fourth quarter 2017 conference call. The call is being webcast live and the replay along with the copy of the press release and earnings presentation will be available on the Investor Relations section of our corporate website.
The results and data we discuss today reflect the consolidated results of Integer for the periods indicated. During our call, we will discuss certain non-GAAP measures. For a reconciliation of these non-GAAP measures, please see the Appendix of today's presentation and the notes to the financial statements in today's earnings release.
As a reminder, today’s presentation includes forward-looking statements. Please refer to our SEC filings for discussion of the risk factors that could cause our actual results to differ materially. Unless otherwise noted, our commentary today refer to our organic results which adjust for the impact of foreign exchange and any M&A activity during the relevant period.
On our call today to discuss our quarterly results, our 2018 business outlook and our refocus strategy are Joe Dziedzic, President and Chief Executive Officer, and Gary Haire, Executive Vice President and Chief Financial Officer. Following their prepared remarks, the call operator will come back on the line for Q&A.
I'd now like to turn the call over to Joe.
Thanks, Amy. Welcome everyone, and thank you for joining to hear about our fourth quarter results. I am happy to share with you another quarter of continued improvement. In fact, our highest sales and profit quarter in Integer was formed 2.5 years ago.
But before we get into results of the quarter, I want to start by thanking all of our Integer Associates for delivering another quarter of strong topline and net income growth and continued strong cash flow. The teams and the manufacturing plant and everyone supporting them delivered not only strong fourth quarter results, but a strong 2017 as well. The positive trajectory is clear. Thank you.
Now let’s review of fourth quarter results. Our fourth quarter results demonstrates strong revenue growth of 8% and net income growth of 28%. We continue to generate strong cash flow from operations and pay down $129 million of debt during 2017. Gary will take you through the financials, but I want to highlight that we finished the year above our original guidance on sales and at the high end on a EPS.
We understand our credibility with our customers is based on delivering on our commitment and it is no different with our investors. Today we introduced our new strategy to drive accelerated sales and profit growth. Late last year, we completed a comprehensive strategic review of all aspects of our business and developed our new strategy which is focused on portfolio management and operational excellence.
Within portfolio management, we organized our product lines into three groups, which are invest to grow, protect and preserve and improve profitability. I’ll cover our strategy in more detail later in the presentation.
Turning to Slide 6, annual sales growth consistently improved throughout 2017 and we closed the year with organic growth of 5% for 2017 reflecting the progress we have made to change their trajectory of our sales back to growth. Every product line improved their trajectory either going from a decline in 2016 to growth in 2017, or slowing the rate of decline. 2017 was an inflection point for Integer back to growth.
Gary will now provide more discussion regarding our financial results for the quarter and the full-year.
Thanks Joe, and good afternoon.
I’m going to take you through our fourth quarter and full-year 2017 financial results. And then I will also take you through our 2018 full-year outlook. Consistent with prior quarters, any reference to organic when we are referring to sales excludes the impact of foreign exchange and M&A activity. Any reference to organic as we talk about adjusted EBITDA, adjusted net income and adjusted EPS excludes the impact of foreign currency gains and losses that are reported in nonoperating other income or expense.
Turning to Slide 8. Here's a quick look at our results for the fourth quarter. Sales increased 7.6% organically closing out the year with record sales in our fourth quarter. In the quarter we saw growth accelerate in all of our medical product lines and continued double-digit growth in our Electrochem business.
Adjusted EBITDA increased 11% year-over-year and during the quarter we incurred just under $1 million of losses due to foreign exchange impacted by the continued strengthening of the euro versus the dollar. However, the impact is lower this quarter due to restructuring actions we took to reduce our exposure. Excluding this FX impact, and taking into account the foreign exchange gain in last year's number which was $3 million, adjusted EBITDA would have been up nearly 17% year-over-year.
Our adjusted net income increased 28% organically when you exclude the impact of the FX losses I just mentioned. Adjusted EPS was $0.96 on a reported basis and includes $0.02 related to the FX. And also worth noting is that our EPS was impacted by about $0.04 from share dilution year-over-year for a total of about $0.06 from these two items. Overall, we had really strong finish to the year with solid execution.
Now moving to Slide 9. You could see that fourth quarter adjusted EBITDA and adjusted net income and EPS all had double-digit growth year-over-year on an organic basis. Organically adjusted EBITDA increased 17% year-over-year in the quarter. This can be attributed to our stronger sales volumes, as well as improved gross margin which was up a full percentage point versus last year.
Organic growth was up 28% for adjusted net income and up 24% for adjusted EPS. This growth included unfavorable year-over-year impact of higher incentive compensation which amounted to about $11 million versus last year's Q4. These higher costs were driven by our stronger performance as we finished the year.
On Slide 10, I want to summarize our full year 2017 results. Looking at sales, we had a strong year with 5.3% organic growth. This was led by the Electrochem business growing almost 37%, as well as organic growth of 9% in Cardio & Vascular and almost 6% growth in AS&O. This was partially offset by the decline of about 2% in Cardiac & Neuro.
Adjusted EBITDA was up 7% organically which excludes the impact of FX year-over-year. Impacting adjusted EBITDA for the year, was a headwind of approximately $14 million of bonus expense or nonstock incentive compensation given the improved performance versus the prior year and the company meeting its operating metrics.
Adjusted net income was up 23% organically which is driven by the improved operating performance, lower interest expense and the lower adjusted effective tax rate which was about 20% in 2017 versus 23% in 2016.
Now looking at Slide 11. I want to compare our actual results versus our original guidance that was provided at the beginning of 2017. For sales as we have discussed, we were well above our original guidance range driven by stronger sales than we expected in both the medical and nonmedical business with a combination of better execution across the business in better than expected markets specifically in Electrochem. For adjusted EPS, we're well within the range on a reported basis that were near the high-end of the range when you exclude the impact of FX that FX had on us for the year.
Now turning to cash flow on Slide 12. I want to make a few comments around our 2017 cash flow, our debt, leverage, as well as give you some thoughts on our 2018 outlook. As I mentioned before, we're committed to generating continued and sustainable operating cash flow, as well as reducing leverage. We finished the year by generating $34 million of operating cash flow during the fourth quarter for a total of 149 million for the full-year. And this translated into $103 million of free cash flow.
Our strong cash flow allowed us to accelerate debt payment throughout the year and we repaid $129 million of debt in 2017, consisting of $98 million in accelerated payments. In addition, we reduced our leverage from 6.1 to 5.6 during the year.
Now looking forward to 2018, we will continue to focus on cash flow and reducing our leverage. We anticipate generating over $150 million of operating cash flow and over $100 million of free cash flow in 2018. And we will continue to reduce our leverage with an initial goal of getting below 5.0.
With our strong cash flow generation and our efforts to effectively manage working capital, our near-term debt and interest payments remain very manageable. We will continue to monitor markets on a regular basis and evaluate additional opportunities as appropriate, particularly as we move into the back half of the year and look at our existing high-yield notes.
Now turning to Slide 18, I'd like to now discuss our full-year outlook for 2018. We expect 2018 full year sales growth to be between 2% and 5% for the year. We believe our revenue outlook appropriately balances product line growth opportunities, as well as market realities and our customer programs.
For adjusted EBITDA, we're expecting a range of $305 million to $315 million which would be a growth rate of approximately 7% to 10%. We expect 2018 full-year adjusted earnings per share to be in the range of $3.15 to $3.45, an increase of 17% at the midpoint of the guidance.
In addition to this guidance, I also want to provide you with some additional information for 2018. We expect capital expenditures to be in a range of $50 million to $55 million for the year and depreciation and amortization to be in the range of $106 million to $108 million.
Stock-based compensation is expected to be in a range of $10 million to $12 million for the year and for other operating expenses, we're expecting to spend approximately $10 million to $15 million which is a significant reduction from prior years as the majority of our spending on acquisition and integration activities is now behind us.
The 2018 adjusted effective tax rate is expected to be in a range of 20% to 25% and cash back payments are expected to be between $13 million and $15 million for the year. Now in regards to the tax rate, it is very important to note that we're still in the process of analyzing implications of the new Tax Law. Given both the magnitude of the changes involved and that we expect further clarification with regard to the application of certain provisions of the legislation, we're providing a broader range than normal and we've assumed the current target in the middle of this range for our guidance.
Now I want to switch gears and I'll cover our product line sales results and then I will turn it back to Joe to cover our new strategy. First starting to Advanced Surgical, Orthopedics and Portable Medical. Sales growth year-over-year was up 11% in the fourth quarter driven by a continued tailwind from one customer's accelerating its sales related to one of their initiatives. Continued ramping up of new products, as well as increased development work which can be lumpy. We expect that we will see year-over-year sales growth continue into the first quarter resulting from the completion of transfer activity, as well as new product ramps.
However, we anticipate on offsetting impact in 2018 from the one specific customers inventory management which we expect will lead to a more modest overall growth rate for the full year 2018. Going forward, we believe the large and growing Orthopedic and Advanced Surgical market provides us with significant opportunities to leverage our capabilities in implants, instruments, in arthroscopy in particular.
Turning to Slide 16. The Cardio & Vascular product line has been a significant driver of topline growth for us and we once again saw strong year-over-year sales growth in the quarter driven by continued strong demand for existing Integer own products and increasing demand from contract manufactured products, particularly in areas of vascular access and will peripheral vascular.
The rolling four quarter sales trajectory continues to remain strong, consistently staying in high single-digits over the last few quarters driven by the continued success of our Cardio & Vascular product offering in most markets.
Market momentum remains strong and we continue to have success with both large well established customers, as well as emerging and fast growth customers. We're focusing on the faster growing higher value segments like structural heart, peripheral vascular, and electrophysiology. In addition, we are innovating in areas such as developing faster prototyping turnaround capabilities with the goal of accelerating our customers speed to market and overall success.
Looking at Slide 17, sales in the fourth quarter for Cardiac & Neuromodulation stabilized during the quarter where CRM, the markets remains flat. However, our customers experienced a nice return to growth in the quarter.
In Neuromodulation, sales remain strong and these product and our customers continue to gain strength in the market. The rolling four quarter sales trend further reflects the stabilization we saw in the fourth quarter. We expect to return to growth in the first half of 2018 as midyear 2017 supply constraints have then resolved and customer activity continues to improve.
The Neuromodulation market remains a key driver of long-term growth for the product line. There are many opportunities for continued growth. As the market leading medical device outsourcer, we are focused on accelerating Neuromodulation sales to the active support of customers of all sizes in the design, development and manufacture of everything from components to full systems for customer applications.
We continue to execute on our strategy in Cardiac Rhythm Management and Neuro, partnering with customers to provide full component design, development and manufacturing capability that enables success in support growth. We also believe our OEM partners and customers are seeking more comprehensive value-added solutions and supply chain efficiency which Integer is well positioned to provide.
Now on Electrochem. Electrochem delivered another strong quarter of growth on a year-over-year basis up 30% in the quarter which translates into 37% for the year. The product line continued to benefit from a recovering energy market, as well as share gains made during the downturn. Electrochem's outlook for 2018 is positive as the team executes on new business wins and continues to drive sales growth and share gain initiatives. However, we do not expect the same level of high year-over-year growth rates as the energy market have reached the point of stabilization.
I’ll now turn the call back to Joe.
Before we get into the specifics of our updated strategy, I want to provide a little background on the strategic review process we went through last year.
Shortly after becoming interim-CEO, I initiated a very structured three step process to access the strategy that was in place and determine our go forward strategy. The three steps were very straight forward. The first step was an external assessment of the markets we serve. This included emulations of the market size, growth rates, customers, competitors, technology trends, outsourcing trends and market share of the various participants. We developed an objective view of the markets we're competing in to determine what to expect from those markets.
The second step was internally focused on Integer. This step was designed to answer the simple question, what is our strategy and is it working. We reviewed the results of our current strategy to understand our revenue growth rates versus the market, our profitability versus our competitors, our share of wallet with our customers, our technology position, and many others success measures.
The result of this review combined with step one shaped our new strategy. So the final step produced what you see on Slide 20. The knowledge we gained and conclusions drawn from the external and internal assessments on the basis of this strategy.
The left side groups are product lines into three categories, invest to grow, protect and preserve and improve profitability. The importance of understanding these groupings is clear. What should we expect from the markets we're in, given how we are positioned in them which then leads to very product lines specific strategies that enable us to win.
The invest to grow category includes Cardio & Vascular, Neuromodulation and Electrochem. These markets have inherent tailwinds and are expanding. Our customers are innovating to develop new treatments and procedures that drove these markets beyond the existing products. These are markets that should yield higher growth rates and we need to invest accordingly.
The protect and preserve category consist of Cardiac Rhythm Management which is in a low growth in the market. Our Greatbatch-branded product has been and continues to be a strong and well positioned player in this space. We have and continue to innovate for the next-generation of CRM products, to enable our customers to improve patient lives globally.
The improved profitability category contains businesses with growth potential and includes Orthopedics, Advanced Surgical & Portable Medical. These are strong businesses with differentiated capability that serve our customers very effectively and they have significant margin expansion potential.
We are confident the plans we have put in place will address this margin expansion opportunity, some of which have already been implemented. We have taken organizational actions that create increase senior executive focus.
In November last year we moved to the Portable Medical business to Jennifer Bolt, our President of Electrochem. We did this to create additional senior executive focus for both Portable Medical and the Advanced Surgical and Orthopedics business.
Jennifer has done an excellent job of managing the Electrochem business through a market cycle and after about three years in her current role she has grown to have the capacity for a larger leadership role. The Portable Medical team has already implemented both organization structure changes and headcount reductions that create greater accountability and profitability.
In Advanced Surgical and Orthopedics we have revenue growth opportunities that we are executing on which is evident in the 6% revenue growth delivered in 2017. We have already taken very specific actions within Advanced Surgical and Orthopedics to address underperforming investments and increase efficiencies.
Additionally Jeremy Friedman, our COO will shift more of his focus to improving the profitability of the Advanced Surgical and Orthopedics business. I want to be clear we are profitable and very competitive in Advanced Surgical and Orthopedics and Portable Medical.
We have strong growth prospects in both revenue and margin expansion opportunity. We are highlighting the current level of profitability as an area of significant opportunity for Integer. We highlight these opportunities so you as investors understand our overall strategy and where to expect improvements. So I have covered the portfolio strategy and how we are thinking about each of our product lines.
Now I want to cover the operational strategy. We have three areas of focus customers, costs and culture and each area has two strategic imperatives. The first area of focus is customers which is by design. We believe we have the technology, the manufacturing capability and customer relationships to do more for our customers and win more with our customers then we currently do.
In 2017 we made significant progress in growing our business. We need to accelerate and then sustain this growth rate. To accomplish this we’ll be committing senior executive focus on the strategic imperative of sales force excellence.
Market focus innovation is the other customer strategic imperative. Innovation has been and will continue to be a critical part of the DNA of Integer. Innovation drives the breadth of our offering and the customer we serve. We will continue to partner with our customer to support their innovation while also being at the forefront of MDO innovation to extend the reach of our customers beyond their internal capabilities and resources.
The second area of focus is costs. In addition to delivering innovative high-quality products on time we must generate greater efficiency in our operations to increase capacity and lower costs. To accomplish this we are initiating two strategic imperatives focused on manufacturing excellence and business process excellence.
The manufacturing excellence strategic imperative will create the Integer production system. A single manufacturing approach used across Integer that standardizes and deploys consistent capabilities, tools and processes and ultimately creates and even greater competitive advantage for Integer.
The other cost strategic imperative is business process excellence. We have integrated many businesses over the past five years to become Integer. Now we're taking a very structured approach to create single standard processes across all of Integer. This will generate increased efficiencies and create capacity to focus even more resources to invest to grow with our customers.
The third focus area is culture. Performance excellence to us is a mindset it’s about the level of performance we expect. Excellence must be the standard but excellence doesn't happen on its own. So we're developing or enhancing necessary processes and programs to create a culture of performance excellence including strategic workforce planning, performance differentiation, incentive compensation changes and high potential employee development. The long-term success of Integer is dependent on our ability to increase our leadership capability.
Leadership capability is about developing leaders at all levels of the company who can grow as fast or faster than Integer. It’s about succession planning individual development plans and the selection process. We are committing the necessary focus and investments to building leadership capability for the long-term success of Integer. I have summarized our overall strategy and the strategic imperative within the strategy.
Now let’s cover who on the executive team will lead each of the strategic imperatives. But first I have a few updates on the executive leadership team. Jeremy Friedman, our Chief Operating Officer has informed us of his intent to retire at the end of 2018. I want to thank Jeremy for his more than 10 years of service to Integer and a significant positive impact he has had on our company. I have enjoyed learning from and partnering with Jeremy over the past 11 months and I look forward to his continued partnership.
As part of Jeremy transitioning into retirement at year-end we're moving the Cardio & Vascular and the Cardiac Rhythm Management & Neuromodulation business to report directly to me. This would create capacity for Jeremy to focus on two important elements of our strategy which are improving the profitability of the Advanced Surgical and Orthopedics business and leading our customer strategic imperatives.
Our new President of the Cardio & Vascular business is Payman Khales who joined us this week and brings a strong commercial and general management background to Integer. I am confident Payman is the right person to lead our Cardio & Vascular business as we work to accelerate the Cardio & Vascular business to double-digit growth.
I want to take a moment to thank John Harris who has been leading the Cardio & Vascular business as Interim President very well for more than a year. I'm grateful for John’s leadership and the progress the Cardio & Vascular business made under his guidance. John is staying with the company in his prior role of Vice President of Operations for Cardio & Vascular and he will be a vitally important partner with Payman.
Kirk Thor joined Integer at the beginning of the year as the Chief Human Resources Officer. Kirk brings more than 25 years of talent management and leadership development expertise. And I look forward to partnering with Kirk to drive our culture, strategic, imperatives. The right hand side of this slide highlights the executive leaders who are leading the strategic imperatives. I have already mentioned that Jeremy is leading the customer strategic imperatives and Kirk is leading the culture, strategic imperatives.
The manufacturing excellence strategic imperative is being led by Jennifer Bolt prior to the acquisition of Lake Region Jennifer led operational excellence for Greatbatch and brings a deep manufacturing background in the automotive industry. Business process excellence is being co-led by our Executive Vice President of Quality & Regulatory Joe Flanagan and our Chief Information Officer Mary Holler. Both Joe and Mary have deep expertise in process excellence that positions them well to lead this important strategic imperative across Integer.
We have a clear strategy to accelerate growth both from a portfolio perspective and an operational perspective. The strategic imperatives are clear. We have the management team in place with the recent additions of Kirk and Payman. We have clear executive ownership of the strategic imperatives more importantly the executive leaders have deep, domain expertise in the strategic imperatives they are leading. We have clear financial measures of success.
Sales growth above the market and profit growth at least two times sales growth which we believe will earn a valuation premium. I am confident we have the right strategy and the right team in place to deliver for our customers and to realize our vision of enhancing patient’s lives worldwide.
Joey let’s open it up for questions.
[Operator Instructions] Your first question comes from the line of Matthew Mishan from KeyBanc. Your line is open.
I guess first off congratulations on presenting a very thorough and really well thought out plan to grow the business. Have you had the opportunity to present this to some of your customers and I just want to get their first reaction to it?
I will have the chance to do that on Tuesday of next week when I’m meeting with the customer. We have just unveiled this publicly today. We've been working on this obviously since the middle of last year. Internally we’ve been rolling this out over the past couple of weeks. So this is the first public announcement of this. So next week on Tuesday I'll be with the customer and I’ll get some initial impressions.
And on the last slide you put clear objectives over there and the objectives are to grow faster than the market and to earn valuation premium. What is your sense of what the market is now growing at, what has it been growing at. And then who you're trying to earn valuation premium to?
So we think the markets when you look at all of the markets that we’re competing in and you aggregate, we think it’s mid single digits maybe somewhere in the 4% to 5% range and we’re looking at this and thinking about it over a long time period not a discrete quarter or year. So as we think about over time, we’re thinking 4% to 5% as the market.
So we aspire to be excellent which is above the market, above average and when we think about earning the valuation premium, there's not a lot of clear MDO public company comps. So as we look at companies that we think might be similar to us on other factors whether its size or being an industry but not the specific markets, or we look at other deals that have occurred and we look at the value, we think market for us is somewhere in the low to mid-teens in terms of our multiple of EBITDA where we're trading at a discount to that today and our objective is to earn a premium. We believe that if we deliver above market growth and we bring profit through it at least two times the revenue growth that will earn a premium.
And then how much of visibility do you have to growth. I mean do you have any idea of how much is - of the plan of the 2% to 5% next year. How much of that is new business wins or core volumes, and have you better aligned with your customers so that you are able to plan alongside them. Better so then you had over like the previous several years?
So, if your question is more about short-term understanding our customer's needs and their volume demands, I think we’ve made tremendous progress in the past couple of years and I’ll specifically point to what Jeremy Friedman our COO has done in building that process out to work with customers for our sales, operations planning process. I think we're well aligned with our customers and we understand their near-term needs from a production and delivery perspective. And I think we delivered very effectively in the fourth quarter and that was part of our success in the fourth quarter.
What you may be asking more of is as we look beyond 2018 and how do we earn and - above market growth rate that's where our strategic imperatives for customers comes into play. The sales force excellence is about us making sure that we’re getting full value for what we currently have in terms of technology, manufacturing capability and how we can support our customer’s growth.
I think what we have today should allow us to grow at least the market rate which we did in 2017. Looking backwards over time we have it but I think 2017 we are and expect to figure that up and look forward to grow at least the market rate and I think sales force excellence can get us there.
The market focus innovation is how we get to grow above the market above what the market rate is by partnering with our customers in bringing innovative products and solutions to them. Jeremy is going to spend the rest of the 2018 focused on these two strategic imperatives to ensure that as we go into 2019 we have clear line of sight as to how we’re going to deliver above market growth.
Just last question for Gary. How should we - maybe I missed it in the presentation but how should we be thinking about interest expense in 2018 especially in kind of rising rate environment?
So from an interest expense standpoint and I’ll just stay to the cash side, the amortization of the deferred cost is going to be flat its around $7 million, but the cash side interest, we were about $96 million of cash interest in 2017. And as we look forward, we expect the cash interest to be down just a little bit and really to think about it is we have obviously heavy debt paydown. So we have a lower balance, but certainly the LIBOR is up. Right now, what we’re modeling is about kind of a weighted average rate up around 40 basis points year-over-year due to the LIBOR increases and that’s way I would look at it.
[Operator Instructions] Your next question comes from the line of Jim Sidoti from Sidoti. Your line is open.
If we go back three months and we listen to the tone on the call there, it sounded like you expected topline growth to moderate a little bit in the fourth quarter. And the numbers you reported today were very, very strong. Were you surprised to see how the business grew in the fourth quarter?
Jim thanks for the question. We absolutely did see stronger demand from customers in the fourth quarter then what we were anticipating. I’d say there were multiple factors that led to our outperformance in the fourth quarter versus our guidance. And it started with we executed. We fulfilled everything our customer ordered, and what they needed.
The customer demand was stronger, you see the stronger revenues in their results based on their releases. And as we were entering the fourth quarter we were looking at 2016 and the fourth quarter 2016 was by far the biggest quarter of the year.
And so as we were looking to our fourth quarter 2017 demand to think that we were going to be 8% over the highest quarter of 2016 was not what we were expecting obviously given our guidance. So we did perform better in terms of delivery in the fourth quarter and our customer demand was better. So we feel really good about entering 2018 with the momentum we have.
And then other than that one customer that was rebuilding some inventory in the quarter, I mean were there anyone - any sales that you would consider pull forward or one-time in the quarter and you think that…?
No, there was not in fact the one customer that was something we actually knew about early in the third quarter because it was a specific program for something that they’re working on. So we knew about that going into the third quarter. So that impact was customer driven and it was in our guidance going into the fourth quarter.
And then this is a same question I asked you three months ago, that was when do you think that the declines in the CRM business will be more than offset by the growth in the neuro business?
I know everyday we’re getting more and more traction in neuro and everyday our neuro customers continue to grow and perform well. I don't know when that tipping point comes but I want it sooner than you do.
Well based on your guidance for 2018 it sounds like we’re pretty close?
We believe there's opportunity for us in the Cardiac Rhythm Management business to actually make some inroads in certain segments that can allow us to get some growth despite the low growth in CRM in total. So even though it’s in protective reserve because we’re broadly well-positioned, we do see some segments of growth opportunity. We have to go execute and deliver for our customers which we’re working on.
So we’re not giving up on growth in CRM but we recognize the realities of that market. And neuro we’re going to be very focused on accelerating the growth there and serving the high growth customers in that space. We don’t know exactly when that tipping points going to come but we’re focused on it.
And then the last question from me is on debt paydown, it sounds like you’re going to pay a little bit less debt in 2018 than you did in 2017 even though EPS should be greater. Is there a reason for that, is that cash being used for investments or what's going on there?
Jim, its Gary. So I think that what you’re seeing is a 100 plus on the debt paydown. I don’t know that I directly interrupt that as we’re going to paydown less. We generated really solid cash flow in 2017 on top of the cash flow that we generated operationally or free cash flow in 2017. We had couple other things that went to the debt payments which was one, we effectively use a little bit more cash to draw our cash balance down which we think is a prudent thing, we'll continue to do and also we got some cash in from stock option exercises probably more than a normal rate during this last year. So we had that excess cash.
But I don’t know that would interpret as we're going to reduce our debt paydown from 2017 to 2018 maybe it's just - I’m not given specific guidance around it just for some possibility. But I wouldn’t say that it’s a change in the investments, yes that level should be pretty comparable as I said on the capital investments but I don’t think you should read too much into that.
There are no further questions at this time. I’ll turn the call back over to the presenters.
Thanks Joey. Thanks for taking time to join our call and for your continued interest in Integer. If you have any follow-up questions, please contact Investor Relations directly. Have a great evening.
This concludes today's conference call. You may now disconnect.